ADMA Biologics
ADMA • NASDAQ
ADMA Biologics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Adam S. Grossman, with a market cap of $2.2B.
CEOAdam S. Grossman
Next Earnings
Upcoming earnings announcement for ADMA Biologics
Date
Wednesday, May 6, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.21
Revenue Estimate
$142.8M
Earnings History
Past 12 earnings reports for ADMA Biologics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Q4 2025 | $0.22Est: $0.20 | +7.5% | $139.2MEst: $139.8M | -0.5% |  10-K |
| Nov 5, 2025 | Q3 2025 | $0.16Est: $0.16 | 0.0% | $134.2MEst: $130.4M | +3.0% | 10-Q |
| Aug 6, 2025 | Q2 2025 | $0.14Est: $0.14 | 0.0% | $122.0MEst: $121.5M | +0.4% | 10-Q |
| May 7, 2025 | Q1 2025 | $0.14Est: $0.14 | 0.0% | $114.8MEst: $116.4M | -1.4% | 10-Q |
| Mar 3, 2025 | Q4 2024 | $0.14Est: $0.15 | -6.7% | $117.5MEst: $112.8M | +4.2% | 10-K |
| Nov 7, 2024 | Q3 2024 | $0.15Est: $0.13 | +15.4% | $119.8MEst: $105.9M | +13.2% | 10-Q |
| Aug 8, 2024 | Q2 2024 | $0.13Est: $0.08 | +62.5% | $107.2MEst: $86.4M | +24.0% | 10-Q |
| May 9, 2024 | Q1 2024 | $0.08Est: $0.05 | +60.0% | $81.9MEst: $77.3M | +6.0% | 10-Q |
| Feb 28, 2024 | Q4 2023 | $0.04Est: $0.02 | +100.0% | $73.9MEst: $72.2M | +2.4% | 10-K |
| Nov 8, 2023 | Q3 2023 | $0.01Est: -$0.01 | +200.0% | $67.3MEst: $62.1M | +8.3% | — |
| Aug 9, 2023 | Q2 2023 | -$0.03Est: -$0.02 | -50.0% | $60.1MEst: $55.5M | +8.3% | 10-Q |
| May 10, 2023 | Q1 2023 | -$0.03Est: -$0.04 | +25.0% | $56.9MEst: $53.4M | +6.6% | — |